EMMA Emmaus Life Sciences Inc
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. It engages in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. The company is headquartered in Torrance, CA.
Company profile
Ticker
EMMA
Exchange
CEO
Yutaka Niihara
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
Former names
Age Research Inc, CNS Response, Inc., MYnd Analytics, Inc., SalesTactix, Inc., Strativation, Inc.
SEC CIK
Corporate docs
IRS number
870419387
EMMA stock data
()
Investment data
Securities sold
Number of investors
Calendar
14 Aug 19
13 Nov 19
31 Dec 19
News
Company financial data Financial data
| Quarter (USD) | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|
| Revenue | 527K | 460.1K | 387.1K | 341.9K | |
| Net income | -2.12M | -2.26M | -2.38M | -1.64M | |
| Diluted EPS | -0.2 | -0.27 | -0.32 | -0.2 | |
| Net profit margin | -403% | -491% | -614% | -479% | |
| Operating income | -2.7M | -2.68M | -2.68M | -1.94M | |
| Net change in cash | 1.24M | -296.6K | -1.75M | 608K | |
| Cash on hand | 2.44M | 1.2M | 1.5M | 3.25M | |
| Cost of revenue | 407.6K | 296.3K | 225.1K | 200K |
Financial data from company earnings reports
Financial report summary
?Management Discussion
- MYnd Analytics is focused on research and the commercialization of its PEER Reports through its Neurometric Services, as well as providing telehealth service through scheduling and videoconferencing which is accessed through a secure portal.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
accelerated, Agent, andnine, biopharmaceutical, counsel, CUSIP, debenture, deficiency, department, detected, disease, documentation, EAP, effort, EMI, EMMA, EMMAW, employed, Endari, ensure, European, fewer, FirstMed, formal, formalizing, heard, henceforth, holding, inclusive, infringement, joint, knowledge, lead, light, misstatement, monitoring, multiplied, MYNDW, organization, orphan, OTC, partially, percentage, Pink, promissory, proper, properly, proportional, proxy, rare, scientific, similarly, staffed, Tele, toConsolidated, treated, unexercised, Union, unsuccessful
Removed:
Administration, alleged, arising, broader, CEO, certified, commercialize, committee, compete, convincing, coverage, created, decline, delay, device, Drug, evolving, expect, fluctuate, Food, found, gain, governmental, harmed, hinder, implied, imposition, injury, longer, modification, oral, pending, personal, prevail, prevent, prorated, protect, rEEG, regain, retroactive, salary, security, sell, team, therewith, trade, unfavorable, widespread, work
Financial reports
10-Q
2019 Q3
Quarterly report
14 Aug 19
10-Q
2019 Q2
Quarterly report
13 May 19
10-Q
2019 Q1
Quarterly report
14 Feb 19
10-K
2018 FY
Annual report
11 Dec 18
10-Q
2018 Q3
Quarterly report
10 Aug 18
10-Q
2018 Q2
Quarterly report
14 May 18
10-Q
2018 Q1
Quarterly report
20 Feb 18
10-K
2017 FY
Annual report
29 Dec 17
10-Q
2017 Q3
Quarterly report
14 Aug 17
10-Q
2017 Q2
Quarterly report
15 May 17
Current reports
8-K
Emmaus Life Sciences Reports 2019 Third Quarter Financial Results
12 Nov 19
8-K
Emmaus Life Sciences Announces Equity Investment from a Corporate Investor
29 Oct 19
8-K
Changes in Registrant's Certifying Accountant
24 Oct 19
8-K
Emmaus Life Sciences Reports Preliminary Gross Sales for the About Emmaus Life Sciences
11 Oct 19
8-K
Departure of Directors or Certain Officers
1 Oct 19
8-K
Amendments to Articles of Incorporation or Bylaws
30 Sep 19
8-K
Emmaus Life Sciences to be Delisted from Nasdaq Stock Market Following Hearing
10 Sep 19
8-K/A
2019 Q2
Financial Statements and Exhibits
14 Aug 19
8-K
Unaudited Pro Forma Condensed Combined Financial Statements
22 Jul 19
8-K
Submission of Matters to a Vote of Security Holders
12 Jul 19
Registration and prospectus
25-NSE
Exchange delisting
8 Nov 19
424B5
Prospectus supplement for primary offering
25 Oct 19
S-8
Registration of securities for employees
12 Sep 19
425
Business combination disclosure
9 Jul 19
424B3
Prospectus supplement
14 Jun 19
S-4/A
Registration of securities issued in business combination transactions (amended)
11 Jun 19
S-4/A
Registration of securities issued in business combination transactions (amended)
10 Jun 19
424B5
Prospectus supplement for primary offering
24 May 19
425
Business combination disclosure
23 May 19
425
Business combination disclosure
13 May 19
Proxies
DEF 14A
Definitive proxy
2 Nov 18
PRE 14A
Preliminary proxy
23 Oct 18
DEF 14A
Definitive proxy
1 Mar 18
DEFA14A
Additional proxy soliciting materials
15 Aug 17
DEF 14A
Definitive proxy
27 Jul 17
PRE 14A
Preliminary proxy
25 Apr 17
DEF 14A
Definitive proxy
6 Oct 16
DEF 14A
Definitive proxy
6 Oct 15
PRER14A
Preliminary revised proxy
30 Sep 15
PRE 14A
Preliminary proxy
18 Sep 15
Other
EFFECT
Notice of effectiveness
12 Jun 19
UPLOAD
Letter from SEC
30 May 19
CORRESP
Correspondence with SEC
9 May 19
UPLOAD
Letter from SEC
2 May 19
EFFECT
Notice of effectiveness
24 Dec 18
EFFECT
Notice of effectiveness
2 Jul 18
EFFECT
Notice of effectiveness
8 Jun 18
EFFECT
Notice of effectiveness
8 Jun 18
EFFECT
Notice of effectiveness
13 Jul 17
CORRESP
Correspondence with SEC
12 Jul 17
Ownership
SC 13G/A
Emmaus Life Sciences, Inc.
5 Sep 19
SC 13G
Emmaus Life Sciences, Inc.
26 Aug 19
SC 13G/A
Emmaus Life Sciences, Inc.
23 Aug 19
SC 13D
Emmaus Life Sciences, Inc.
2 Aug 19
SC 13G
MYnd Analytics, Inc.
7 Jun 19
SC 13G
MYnd Analytics, Inc.
5 Jun 19
SC 13G
MYnd Analytics, Inc.
5 Jun 19
SC 13D
MYnd Analytics, Inc.
30 Nov 18
SC 13D/A
MYnd Analytics, Inc.
30 Nov 18
SC 13G/A
MYnd Analytics, Inc.
1 Oct 18